BACKGROUND: The analysis of bodily fluids using SELDI-TOF MS has been reported to identify signatures of spectral peaks that can be used to differentiate patients with a specific disease from normal or control patients. This report is the 2nd of 2 companion articles describing a validation study of a SELDI-TOF MS approach with IMAC surface sample processing to identify prostatic adenocarcinoma. METHODS: We sought to derive a decision algorithm for classification of prostate cancer from SELDI-TOF MS spectral data from a new retrospective sample cohort of 400 specimens. This new cohort was selected to minimize possible confounders identified in the previous study described in the companion paper. RESULTS: The resulting new classifier failed to separate patients with prostate cancer from biopsy-negative controls; nor did it separate patients with prostate cancer with Gleason scores <7 from those with Gleason scores > or =7. CONCLUSIONS: In this, the 2nd stage of our planned validation process, the SELDI-TOF MS-based protein expression profiling approach did not perform well enough to advance to the 3rd (prospective study) stage. We conclude that the results from our previous studies-in which differentiation between prostate cancer and noncancer was demonstrated-are not generalizable. Earlier study samples likely had biases in sample selection that upon removal, as in the present study, resulted in inability of the technique to discriminate cancer from noncancer cases.
BACKGROUND: The analysis of bodily fluids using SELDI-TOF MS has been reported to identify signatures of spectral peaks that can be used to differentiate patients with a specific disease from normal or control patients. This report is the 2nd of 2 companion articles describing a validation study of a SELDI-TOF MS approach with IMAC surface sample processing to identify prostatic adenocarcinoma. METHODS: We sought to derive a decision algorithm for classification of prostate cancer from SELDI-TOF MS spectral data from a new retrospective sample cohort of 400 specimens. This new cohort was selected to minimize possible confounders identified in the previous study described in the companion paper. RESULTS: The resulting new classifier failed to separate patients with prostate cancer from biopsy-negative controls; nor did it separate patients with prostate cancer with Gleason scores <7 from those with Gleason scores > or =7. CONCLUSIONS: In this, the 2nd stage of our planned validation process, the SELDI-TOF MS-based protein expression profiling approach did not perform well enough to advance to the 3rd (prospective study) stage. We conclude that the results from our previous studies-in which differentiation between prostate cancer and noncancer was demonstrated-are not generalizable. Earlier study samples likely had biases in sample selection that upon removal, as in the present study, resulted in inability of the technique to discriminate cancer from noncancer cases.
Authors: M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui Journal: J Natl Cancer Inst Date: 2001-07-18 Impact factor: 13.506
Authors: Harald Mischak; Rolf Apweiler; Rosamonde E Banks; Mark Conaway; Joshua Coon; Anna Dominiczak; Jochen H H Ehrich; Danilo Fliser; Mark Girolami; Henning Hermjakob; Denis Hochstrasser; Joachim Jankowski; Bruce A Julian; Walter Kolch; Ziad A Massy; Christian Neusuess; Jan Novak; Karlheinz Peter; Kasper Rossing; Joost Schanstra; O John Semmes; Dan Theodorescu; Visith Thongboonkerd; Eva M Weissinger; Jennifer E Van Eyk; Tadashi Yamamoto Journal: Proteomics Clin Appl Date: 2007-01-22 Impact factor: 3.494
Authors: Gunjan Malik; Michael D Ward; Saurabh K Gupta; Michael W Trosset; William E Grizzle; Bao-Ling Adam; Jose I Diaz; O John Semmes Journal: Clin Cancer Res Date: 2005-02-01 Impact factor: 12.531
Authors: Yinsheng Qu; Bao-Ling Adam; Yutaka Yasui; Michael D Ward; Lisa H Cazares; Paul F Schellhammer; Ziding Feng; O John Semmes; George L Wright Journal: Clin Chem Date: 2002-10 Impact factor: 8.327
Authors: Stephane Decramer; Stefan Wittke; Harald Mischak; Petra Zürbig; Michael Walden; François Bouissou; Jean-Loup Bascands; Joost P Schanstra Journal: Nat Med Date: 2006-03-19 Impact factor: 53.440
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: William E Grizzle; O John Semmes; William Bigbee; Liu Zhu; Gunjan Malik; Denise K Oelschlager; Barkha Manne; Upender Manne Journal: Cancer Inform Date: 2005
Authors: Henrik Ryberg; Jiyan An; Samuel Darko; Jonathan Llyle Lustgarten; Matt Jaffa; Vanathi Gopalakrishnan; David Lacomis; Merit Cudkowicz; Robert Bowser Journal: Muscle Nerve Date: 2010-07 Impact factor: 3.217
Authors: Lynn M Amon; Wendy Law; Matthew P Fitzgibbon; Jennifer A Gross; Kathy O'Briant; Amelia Peterson; Charles Drescher; Daniel B Martin; Martin McIntosh Journal: PLoS One Date: 2010-06-15 Impact factor: 3.240